Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Immunosuppressive treatment for interstitial lung disease in systemic sclerosis: effectiveness in mild and late clinical subtypes
FY 2016-17
Summary
Scleroderma (or systemic sclerosis, SSc) is an autoimmune disease characterized by thickening and hardening of the skin. In up to half of patients, the immune system can also attack the lungs and lead to interstitial lung disease (ILD). ILD can lead to severe shortness of breath, cough and decreased endurance to exercise, and is now the leading cause of death in SSc. To date, three randomized controlled trials have studied the effectiveness of medications that suppress the immune system in patients with SSc-ILD, targeting those with early disease and significant impairment in lung function. At present, the benefits and risks of immunosuppression in those with milder lung disease or more prolonged disease, who represent the majority of scleroderma lung disease patients, remain uncertain. In this study, we aim to determine whether immunosuppressive drugs are effective in SSc-ILD patients with milder lung disease at baseline or longer disease duration. Using the data from the Canadian Scleroderma Research Group registry, we will first identify patients diagnosed with ILD and assess change in lung function over time, comparing those who are treated and not treated with immunosuppressive drugs. Then, we will compare these results among those with mild and severe disease (i.e. lung function above and below 80% expected), and among those with early and late disease (i.e. disease duration less or more than 7 years). To our knowledge, this study will be the first to assess the effectiveness of immunosuppression in mild and late subgroups of SSc-ILD. It has the potential to inform and change clinical practice. In addition, it will provide a rationale to pursue further studies in subgroups of SSc-ILD patients that have to date been excluded from such studies.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367130
Name
Hoa Sabrina A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Immunosuppressive treatment for interstitial lung disease in systemic sclerosis: effectiveness in mild and late clinical subtypes
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Immunosuppression; Interstitial Lung Disease; Systemic Sclerosis (Or Scleroderma)
Abstract
Scleroderma (or systemic sclerosis, SSc) is an autoimmune disease characterized by thickening and hardening of the skin. In up to half of patients, the immune system can also attack the lungs and lead to interstitial lung disease (ILD). ILD can lead to severe shortness of breath, cough and decreased endurance to exercise, and is now the leading cause of death in SSc. To date, three randomized controlled trials have studied the effectiveness of medications that suppress the immune system in patients with SSc-ILD, targeting those with early disease and significant impairment in lung function. At present, the benefits and risks of immunosuppression in those with milder lung disease or more prolonged disease, who represent the majority of scleroderma lung disease patients, remain uncertain. In this study, we aim to determine whether immunosuppressive drugs are effective in SSc-ILD patients with milder lung disease at baseline or longer disease duration. Using the data from the Canadian Scleroderma Research Group registry, we will first identify patients diagnosed with ILD and assess change in lung function over time, comparing those who are treated and not treated with immunosuppressive drugs. Then, we will compare these results among those with mild and severe disease (i.e. lung function above and below 80% expected), and among those with early and late disease (i.e. disease duration less or more than 7 years). To our knowledge, this study will be the first to assess the effectiveness of immunosuppression in mild and late subgroups of SSc-ILD. It has the potential to inform and change clinical practice. In addition, it will provide a rationale to pursue further studies in subgroups of SSc-ILD patients that have to date been excluded from such studies.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hoa, Sabrina A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~